Výsledky vyhledávání - "R M, Bergenstal"

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3

Autor: R M, Bergenstal, H, Lunt, E, Franek, F, Travert, J, Mou, Y, Qu, C J, Antalis, M L, Hartman, M, Rosilio, S J, Jacober, E J, Bastyr

Publikováno v: Diabetes, Obesity & Metabolism

Aims To compare the efficacy and safety of basal insulin peglispro (BIL), which has a flat pharmacokinetic and pharmacodynamic profile and a long duration of action, with insulin glargine (GL) in patients with type 1 diabetes. Materials and methods I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a64f3804538d1d7c72193c8966430852
https://doi.org/10.1111/dom.12698

Zobrazit plný text záznamu

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

Autor: G H, Daniels, L, Hegedüs, S P, Marso, M A, Nauck, B, Zinman, R M, Bergenstal, J F E, Mann, J, Derving Karsbøl, A C, Moses, J B, Buse, R M, Tuttle

Publikováno v: Diabetes, Obesity & Metabolism

Aims To report preliminary data on baseline serum calcitonin concentrations and associated clinical characteristics in a global population with type 2 diabetes before liraglutide or placebo randomization. Methods The ongoing LEADER trial has enrolled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b745c2f8e3148873c61f043c0b84822a
https://pubmed.ncbi.nlm.nih.gov/25656058

Zobrazit plný text záznamu

Use of an Automated Device for Alternative Site Blood Glucose Monitoring

Autor: R M Bernstein, Lori M.B. Laffel, S L Schwartz, S E Fineberg, R M Bergenstal

Publikováno v: Diabetes Care. 24:1217-1220

OBJECTIVE—To evaluate the accuracy, comfort, and ease of use of a new automated device for blood glucose monitoring using the arm as an alternative sampling site. RESEARCH DESIGN AND METHODS—These studies use an automated hand-held device that ap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c043db059d7af6f3f46824c8446534a
https://doi.org/10.2337/diacare.24.7.1217

Zobrazit plný text záznamu

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c7%, without weight gain or hypoglycaemia, over 52 weeks

Autor: Carole Weaver, Y. Li, Jenny Han, R. M. Bergenstal, T. K. Booker Porter

Publikováno v: Diabetes, Obesity & Metabolism

Aims: Type 2 diabetes mellitus (T2DM) is often associated with cardiovascular (CV) risk factors such as obesity, hypertension and dyslipidemia. The objective of this analysis was to evaluate potential effects of exenatide once weekly (ExQW), a GLP-1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b620e410fed8621c553d09088a54c61
https://pubmed.ncbi.nlm.nih.gov/23078638

Zobrazit plný text záznamu

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes

Autor: H C, Gerstein, V, Mohan, A, Avezum, R M, Bergenstal, J-L, Chiasson, M, Garrido, I, MacKinnon, P V, Rao, B, Zinman, H, Jung, L, Joldersma, J, Bosch, S, Yusuf

Publikováno v: Diabetologia. 54(3)

The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial reported that 3 years of therapy with rosiglitazone reduced the primary outcome of diabetes or death by 60%. Here we investigated whether an effect on diabetes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::760600430e0e3b5238a9b1aee4d79c3c
https://pubmed.ncbi.nlm.nih.gov/21116607

Zobrazit plný text záznamu

Comprehensive management of patients with type 2 diabetes: establishing priorities of care

Autor: D M, Kendall, R M, Bergenstal

Publikováno v: The American journal of managed care. 7

Type 2 diabetes is a complex metabolic disorder characterized by elevated blood glucose levels and a marked increase in the risk of cardiovascular disease (CVD). The increased CVD risk is caused by a unique cluster of metabolic abnormalities, includi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::91ff5cc2c4ecfce167964db4dea8a34d
https://pubmed.ncbi.nlm.nih.gov/11519398

Zobrazit plný text záznamu

The Metabolic Effects of Biosynthetic Human Proinsulin in Individuals with Type I Diabetes*

Autor: J. Jaspan, P. M. Blix, Alan D. Cherrington, R. M. Bergenstal, Jerrold M. Olefsky, Robert M. Cohen, E. Lever, B. Frank, J. H. Galloway, Kenneth S. Polonsky, Robert R. Revers, Orville G. Kolterman, K. Steiner, A. H. Rubenstein

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 58:973-979

To assess the significance of deficiency of circulating proinsulin in patients with type I diabetes mellitus, we studied the metabolic effects of biosynthetic human proinsulin in 24 patients. After withdrawing insulin, an infusion of proinsulin to ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b4bcbf1af25d110f6222137d75a1ab9
https://doi.org/10.1210/jcem-58-6-973

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání